Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Express Scripts
McKesson
Merck
Baxter
Colorcon
Harvard Business School

Last Updated: November 22, 2019

DrugPatentWatch Database Preview

Details for Patent: 5,604,229

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 5,604,229 protect, and when does it expire?

Patent 5,604,229 protects GILENYA and is included in one NDA.

Protection for GILENYA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirteen patent family members in twelve countries.

Summary for Patent: 5,604,229
Title: 2-amino-1,3-propanediol compound and immunosuppressant
Abstract:2-Amino-1,3-propanediol compounds of the formula (I) ##STR1## wherein R is an optionally substituted straight- or branched carbon chain, an optionally substituted aryl, an optionally substituted cycloalkyl or the like, and R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are the same or different and each is a hydrogen, an alkyl, an aralkyl, an acyl or an alkoxycarbonyl, pharmaceutically acceptable salts thereof and immunosuppressants comprising these compounds as active ingredients. The 2-amino-1,3-propanediol compounds of the present invention show immunosuppressive action and are useful for suppressing rejection in organ or bone marrow tranplantation, prevention and treatment of autoimmune diseases or as reagents for use in medicinal and pharmaceutical fields.
Inventor(s): Fujita; Tetsuro (Muko, JP), Sasaki; Shigeo (Kobe, JP), Yoneta; Masahiko (Kobe, JP), Mishina; Tadashi (Iruma, JP), Adachi; Kunitomo (Iruma, JP), Chiba; Kenji (Iruma, JP)
Assignee: Yoshitomi Pharmaceutical Industries, Ltd. (Osaka, JP) Taito Co., Ltd. (Tokyo, JP)
Application Number:08/244,942
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 5,604,229
Patent Claim Types:
see list of patent claims
Compound; Use;

Drugs Protected by US Patent 5,604,229

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novartis GILENYA fingolimod hydrochloride CAPSULE;ORAL 022527-002 May 11, 2018 RX Yes No   Start Trial   Start Trial Y   Start Trial
Novartis GILENYA fingolimod hydrochloride CAPSULE;ORAL 022527-001 Sep 21, 2010 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 5,604,229

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan4-283281Oct 21, 1992
Japan5-179427Jul 20, 1993
PCT Information
PCT FiledOctober 18, 1993PCT Application Number:PCT/JP93/01515
PCT Publication Date:April 28, 1994PCT Publication Number: WO94/08943

International Family Members for US Patent 5,604,229

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 172711   Start Trial
Canada 2126337   Start Trial
Cyprus 2215   Start Trial
Germany 122011100012   Start Trial
Germany 69321823   Start Trial
Denmark 0627406   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
McKesson
Harvard Business School
Moodys
Baxter
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.